Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aronex Atragen

Executive Summary

NDA amendment expected by July with data from 50 additional patients enrolled after the initial filing of the injectable tretinoin NDA for acute promyelocytic leukemia patients who are unable to take the oral form. Aronex had received a "not approvable" letter after the December 1998 NDA submission (1"The Pink Sheet" Oct. 4, 1999, In Brief). At ASCO, Aronex presented Phase II data included in the NDA. In the 75-patient trial, 56 patients were evaluable. Among newly diagnosed APL patients, complete remission rates were 87%, compared with 55% among all relapsed patients. Complete remission rates were 78% for first relapses that were oral Atragen-naive (Group 1) and 23% for second relapses or relapses that had received oral Atragen within one year (Group 2). "One-year survival was 87%, 62.5% and 23% for newly diagnosed, relapse Groups 1 and 2 patients, respectively," a study abstract states

You may also be interested in...



Aronex Atragen

FDA notified the firm that its injectable tretinoin product for acute promyelocytic leukemia is "not approvable." A scheduled review of the drug by FDA's Oncologic Advisory Committee was previously cancelled (1"The Pink Sheet" Aug. 9, In Brief)

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel